Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
UBS
Boehringer Ingelheim
McKinsey
Express Scripts
Medtronic
Teva
Fish and Richardson
Mallinckrodt
Fuji

Generated: January 21, 2018

DrugPatentWatch Database Preview

Teva Company Profile

« Back to Dashboard

What is the competitive landscape for TEVA, and when can generic versions of TEVA drugs launch?

TEVA has seven hundred and seven approved drugs.

There are seventy-two US patents protecting TEVA drugs and there have been two Paragraph IV challenges on TEVA drugs in the past three years. There are forty-three tentative approvals on TEVA drugs.

There are eight hundred and ninety-three patent family members on TEVA drugs in fifty-two countries and four hundred and ninety-five supplementary protection certificates in fourteen countries.

Summary for Teva
International Patents:893
US Patents:72
Tradenames:467
Ingredients:409
NDAs:707

Drugs and US Patents for Teva

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Teva Branded Pharm ZIAC bisoprolol fumarate; hydrochlorothiazide TABLET;ORAL 020186-001 Mar 26, 1993 AB RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Teva Pharms QUETIAPINE FUMARATE quetiapine fumarate TABLET;ORAL 077745-005 Mar 27, 2012 AB RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Teva PHENTERMINE HYDROCHLORIDE phentermine hydrochloride CAPSULE;ORAL 088614-001 Apr 9, 1984 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Teva CEFACLOR cefaclor TABLET, EXTENDED RELEASE;ORAL 065058-002 Sep 4, 2002 RX No Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Teva Pharms OLANZAPINE AND FLUOXETINE HYDROCHLORIDE fluoxetine hydrochloride; olanzapine CAPSULE;ORAL 077528-002 Jun 19, 2012 AB RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Teva Branded Pharm AUSTEDO deutetrabenazine TABLET;ORAL 208082-002 Apr 3, 2017 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Teva NAPROXEN naproxen TABLET;ORAL 074201-001 Dec 21, 1993 AB RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Teva Pharms DEXMETHYLPHENIDATE HYDROCHLORIDE dexmethylphenidate hydrochloride TABLET;ORAL 077107-001 Jan 29, 2007 AB RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Teva Pharms Usa ATAZANAVIR SULFATE atazanavir sulfate CAPSULE;ORAL 091673-002 Apr 22, 2014 AB RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Teva Pharm AIRDUO RESPICLICK fluticasone propionate; salmeterol xinafoate POWDER;INHALATION 208799-001 Jan 27, 2017 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for Teva

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Teva Branded Pharm QNASL beclomethasone dipropionate AEROSOL, METERED;NASAL 202813-001 Mar 23, 2012 ➤ Subscribe ➤ Subscribe
Teva Branded Pharm SEASONALE ethinyl estradiol; levonorgestrel TABLET;ORAL 021544-001 Sep 5, 2003 ➤ Subscribe ➤ Subscribe
Teva Pharms Usa COPAXONE glatiramer acetate FOR SOLUTION;SUBCUTANEOUS 020622-001 Dec 20, 1996 ➤ Subscribe ➤ Subscribe
Teva Branded Pharm NORDETTE-21 ethinyl estradiol; levonorgestrel TABLET;ORAL-21 018668-001 May 10, 1982 ➤ Subscribe ➤ Subscribe
Teva Branded Pharm QVAR 40 beclomethasone dipropionate AEROSOL, METERED;INHALATION 020911-002 Sep 15, 2000 ➤ Subscribe ➤ Subscribe
Teva Branded Pharm CENESTIN estrogens, conjugated synthetic a TABLET;ORAL 020992-004 Mar 13, 2000 ➤ Subscribe ➤ Subscribe
Teva Pharm ARMONAIR RESPICLICK fluticasone propionate POWDER;INHALATION 208798-002 Jan 27, 2017 ➤ Subscribe ➤ Subscribe
Teva AZILECT rasagiline mesylate TABLET;ORAL 021641-002 May 16, 2006 ➤ Subscribe ➤ Subscribe
Teva Branded Pharm MIRCETTE desogestrel; ethinyl estradiol TABLET;ORAL-28 020713-001 Apr 22, 1998 ➤ Subscribe ➤ Subscribe
Teva Branded Pharm QVAR 40 beclomethasone dipropionate AEROSOL, METERED;INHALATION 020911-002 Sep 15, 2000 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for TEVA drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe for Injection 3.5 mg/vial ➤ Subscribe 10/26/2016
➤ Subscribe Delayed-release Tablets 20 mg ➤ Subscribe 6/3/2015
➤ Subscribe Injection 40 mg/mL, 1 mL pre-filled syringe ➤ Subscribe 2/26/2014
➤ Subscribe Injection 40 mg/mL, 1 mL pre-filled syringe ➤ Subscribe 1/29/2014
➤ Subscribe Tablets 0.15 mg/0.02 mg, 0.15 mg/0.025 mg, 0.15 mg/0.03 mg and 0.01 mg ➤ Subscribe 7/10/2013
➤ Subscribe Tablets 0.5 mg and 1 mg ➤ Subscribe 5/17/2010
➤ Subscribe Tablets 5 mg, 10 mg, 20 mg, 30 mg ➤ Subscribe 11/18/2009
➤ Subscribe Tablets 0.1 mg/0.02 mg and 0.01 mg ➤ Subscribe 11/16/2009
➤ Subscribe Tablets 0.3 mg, 0.45 mg and 0.9 mg ➤ Subscribe 3/19/2009
➤ Subscribe Tablets 0.625 mg ➤ Subscribe 3/2/2009
➤ Subscribe Tablets 1.25 mg ➤ Subscribe 11/3/2008
➤ Subscribe Extended-release Capsule 15 mg and 30 mg ➤ Subscribe 8/11/2008
➤ Subscribe Tablets 0.15 mg/0.03 mg/0.01 mg ➤ Subscribe 1/22/2008
➤ Subscribe Tablets 0.15 mg/0.03 mg ➤ Subscribe 3/29/2004
Premature patent expirations for TEVA

Expiration due to failure to pay maintenance fee

Patent Number Expiration Date
➤ Subscribe ➤ Subscribe
➤ Subscribe ➤ Subscribe

Non-Orange Book US Patents for Teva

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,619,117 Rasagiline formulations and processes for their preparation ➤ Subscribe
5,576,353 Method of treating memory disorders using R-enantiomers of N-propargyl-aminoindan compounds ➤ Subscribe
6,316,504 Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof ➤ Subscribe
7,989,436 Estrogenic compounds and pharmaceutical formulations comprising the same ➤ Subscribe
5,387,612 Use of the R-enantiomers of N-propargyl-1-aminoindan compounds for treating Parkinson's disease ➤ Subscribe
8,227,454 Estrogenic compounds, pharmaceutical compositions and formulations comprising the same ➤ Subscribe
9,737,674 Dose counters for inhalers, inhalers and methods of assembly thereof ➤ Subscribe
5,744,500 Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof ➤ Subscribe
9,174,013 Dose counters for inhalers, inhalers and methods of assembly thereof ➤ Subscribe
6,844,334 (3) and (6) substitued estrogenic compounds ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for Teva Drugs

Supplementary Protection Certificates for Teva Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0022 Belgium ➤ Subscribe PRODUCT NAME: FLUVASTATINE SODIQUE; NAT. REGISTRATION NO/DATE: 151 IS 207 F 4 19960409; FIRST REGISTRATION: GB 0101/0360 19930823
545 Luxembourg ➤ Subscribe PRODUCT NAME: EZETIMIBE EN COMBINAISON AVEC ATORVASTATINE OU LEURS SELS PHARMACEUTIQUEMENT ACCEPTEES, Y COMPRIS ATORVASTATINE SOUS FORME D'ATORVASTATINE CALCIQUE TRIHYDRATEE; FIRST REGISTRATION: 20140910
/2013 Austria ➤ Subscribe PRODUCT NAME: DIMETHOXYDOCETAXEL-ACETONSOLVAT (CABAZITAXEL-ACETONSOLVAT); REGISTRATION NO/DATE: EU/1/11/676/001 20110317
00478 Netherlands ➤ Subscribe PRODUCT NAME: TELMISARTAN, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, EN AMLODIPINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER AMLODIPINEBESILAAT; REGISTRATION NO/DATE: EU/1/10/648/001-028 20101007
C0076 France ➤ Subscribe PRODUCT NAME: SIMEPREVIR OU L'UN DE SES SELS, INCLUANT LE SEL DE SODIUM DE SIMEPREVIR; REGISTRATION NO/DATE: EU/1/14/924 20140514
2015038 Lithuania ➤ Subscribe PRODUCT NAME: RILPIVIRINUM + TENOFOVIRUM DISOPROXILUM; REGISTRATION NO/DATE: EU/1/11/737/001, 2011 11 28, EU/1/11/737/002 20111128
C/GB05/042 United Kingdom ➤ Subscribe PRODUCT NAME: MESYLATE, ESYLATE OR SULFATE SALTS OF N-PROPARGYL-1(R)-AMINOINDAN (RASAGILINE); REGISTERED: UK EU/1/04/304/001 20050221; UK EU/1/04/304/002 20050221; UK EU/1/04/304/003 20050221; UK EU/1/04/304/004 20050221; UK EU/1/04/304/005 20050221; UK EU/1/04/304/006 20050221; UK EU/1/04/304/007 20050221
2008 00035 Denmark ➤ Subscribe PRODUCT NAME: SITAGLIPTIN VALGFRIT I FORM AF ET FARMACEUTISK ACCEPTABELT SALT, ISAER MONOPHOSPHAT, METFORMIN VALGFRIT I FORM AF ET FARMACEUTISK ACCEPTABELT SALT, ISAER HYDROCHLORID
1304992/01 Switzerland ➤ Subscribe PRODUCT NAME: CLINDAMYCINI PHOSPHAS ET TRETINOINUM; REGISTRATION NO/DATE: SWISSMEDIC 62513 28.03.2014
C/GB03/034 United Kingdom ➤ Subscribe PRODUCT NAME: MOXIFLOXACIN AND PHARMACEUTICALLY USABLE HYDRATES AND ACID ADDITION SALTS THEREOF AND THE ALKALI METAL, ALKALINE EARTH METAL, SILVER AND GUANIDINIUM SALTS OF THE UNDERLYING CARBOXYLIC ACIDS AND THE RACEMATES THEREOF; REGISTERED: DE 45263.00.00 19990621; UK PL 000 10/0291 20030313
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Argus Health
Queensland Health
Farmers Insurance
Fish and Richardson
Express Scripts
Deloitte
Chinese Patent Office
Medtronic
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot